RxDoctor Payments Data

Haren Patel

Cardiovascular Disease · Houston, TXNPI 1629458989

Payments from drug & device makers

$1,146in general payments, 2019–2025

Across 33 payments — averaging $34.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$231
  • Novartis$227
  • Heartflow, Inc.$169
  • Kiniksa Pharmaceuticals, Ltd.$134
  • Eisai Inc.$115
  • Inspire Medical Systems, Inc.$75
  • plus $195 from 6 others

What the payments were for

  • Food & beverage$93081%
  • Education$21619%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,146 in reported general payments places this provider in the 25th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$233,989
Medicare patients
1,412
Services billed
3,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban453$495,447
JardianceEmpagliflozin161$133,810
Repatha SureclickEvolocumab143$121,296
XareltoRivaroxaban118$105,798
EntrestoSacubitril/Valsartan63$64,744
FarxigaDapagliflozin Propanediol52$45,254
Praluent PenAlirocumab27$20,669
MultaqDronedarone Hcl12$19,395
Repatha SyringeEvolocumab20$14,690
Ranolazine ErRanolazine112$14,113
Rosuvastatin Calcium678$9,193
Atorvastatin Calcium692$8,420
Metoprolol Succinate575$6,820
Dabigatran EtexilateDabigatran Etexilate Mesylate15$3,703
Losartan Potassium311$3,211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$495,447453 claims
Boehringer IngelheimJardiance$19$133,810161 claims
Johnson & JohnsonXarelto$20$105,798118 claims
NovartisEntresto$227$64,74463 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →